<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical course of a 66-year-old man diagnosed with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> is described </plain></SENT>
<SENT sid="1" pm="."><plain>Chemotherapy including <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> had no effect, and so he was treated with <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>His <z:e sem="disease" ids="C0005967" disease_type="Neoplastic Process" abbrv="">bone tumor</z:e> was treated with localized radiation after two courses of chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>After these treatments, <z:mp ids='MP_0000220'>monocytosis</z:mp> was found and dysplastic changes were noted in the bone marrow </plain></SENT>
<SENT sid="4" pm="."><plain>A cytogenetic study revealed t(9;11)(p22;q23), an abnormality which had previously been absent </plain></SENT>
<SENT sid="5" pm="."><plain>A diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) was newly established, and transformation to <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ANLL) was observed 6 months later </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative doses of melphalan, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and radiation therapy were 432 mg, 4,200 mg, 120 mg, and 4,000 cGy, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The cytogenetic abnormality suggested that this patient's <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/ANLL was related to <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> and not talk to <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, although the dose of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> administered was quite low </plain></SENT>
</text></document>